{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:11:43Z","timestamp":1761664303613,"version":"build-2065373602"},"reference-count":106,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"publisher","award":["P1-170, L3-8203, L3-2622, and J3-9255"],"award-info":[{"award-number":["P1-170, L3-8203, L3-2622, and J3-9255"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Malignant mesothelioma (MM) is characterized by poor prognosis and short survival. Extracellular vesicles (EVs) are membrane-bound particles released from cells into various body fluids, and their molecular composition reflects the characteristics of the origin cell. Blood EVs or their miRNA cargo might serve as new minimally invasive biomarkers that would enable earlier detection of MM or treatment outcome prediction. Our aim was to evaluate miRNAs enriched in serum EVs as potential prognostic biomarkers in MM patients in a pilot longitudinal study. EVs were isolated from serum samples obtained before and after treatment using ultracentrifugation on 20% sucrose cushion. Serum EV-enriched miR-103-3p, miR-126-3p and miR-625-3p were quantified using qPCR. After treatment, expression of miR-625-3p and miR-126-3p significantly increased in MM patients with poor treatment outcome (p = 0.012 and p = 0.036, respectively). A relative increase in miR-625-3p expression after treatment for more than 3.2% was associated with shorter progression-free survival (7.5 vs. 19.4 months, HR = 3.92, 95% CI = 1.20\u201312.80, p = 0.024) and overall survival (12.5 vs. 49.1 months, HR = 5.45, 95% CI = 1.06\u201328.11, p = 0.043) of MM patients. Bioinformatic analysis showed enrichment of 33 miR-625-3p targets in eight biological pathways. Serum EV-enriched miR-625-3p could therefore serve as a prognostic biomarker in MM and could contribute to a more personalized treatment.<\/jats:p>","DOI":"10.3390\/jpm11101014","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T21:23:25Z","timestamp":1633901005000},"page":"1014","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-4458","authenticated-orcid":false,"given":"Katja","family":"Gori\u010dar","sequence":"first","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Holcar","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Mavec","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viljem","family":"Kova\u010d","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana, Zalo\u0161ka 2, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-6855","authenticated-orcid":false,"given":"Metka","family":"Lenassi","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-6649","authenticated-orcid":false,"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2478\/v10019-012-0032-0","article-title":"Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients","volume":"46","author":"Kovac","year":"2012","journal-title":"Radiol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00063198-200307000-00004","article-title":"Benign asbestos pleural diseases","volume":"9","author":"Chapman","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: A literature review","volume":"8","author":"Tessari","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Johnen, G., Gawrych, K., Raiko, I., Casjens, S., Pesch, B., Weber, D.G., Taeger, D., Lehnert, M., Kollmeier, J., and Bauer, T. (2017). Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3375-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1183\/09031936.00153611","article-title":"Population-based survival for malignant mesothelioma after introduction of novel chemotherapy","volume":"40","author":"Damhuis","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1097\/JTO.0b013e318275b346","article-title":"Incidence and survival of malignant pleural mesothelioma in Norway: A population-based study of 1686 cases","volume":"7","author":"Helland","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CAD.0b013e32834d7a1c","article-title":"A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma","volume":"23","author":"Kovac","year":"2012","journal-title":"Anticancer Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2008.09.008","article-title":"Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia","volume":"64","author":"Lee","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ak, G., Metintas, S., Akarsu, M., and Metintas, M. (2015). The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1519-z"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: A critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"Borm","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: Where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/JTO.0b013e31820db377","article-title":"Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: A prospective longitudinal cohort study","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/carcin\/bgz103","article-title":"Biomarkers for malignant pleural mesothelioma: A meta-analysis","volume":"40","author":"Gillezeau","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.21037\/jtd.2017.12.17","article-title":"Biomarkers in the prevention and follow-up of workers exposed to asbestos","volume":"10","author":"Foddis","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: What have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fonc.2019.00740","article-title":"Liquid biopsy in malignant pleural mesothelioma: State of the art, pitfalls, and perspectives","volume":"9","author":"Cavallari","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5301\/JBM.2011.8332","article-title":"Two novel polymorphisms in 5\u2032 flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels","volume":"26","author":"Cristaudo","year":"2011","journal-title":"Int. J. Biol. Markers"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/JTO.0000000000000322","article-title":"A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people","volume":"9","author":"Garritano","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","first-page":"456","article-title":"Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals","volume":"74","author":"Pucci","year":"2017","journal-title":"Occup. Environ. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2478\/raon-2020-0011","article-title":"Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases","volume":"54","author":"Goricar","year":"2020","journal-title":"Radiol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: A meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"46537","DOI":"10.1038\/srep46537","article-title":"Clinical-pharmacogenetic models for personalized cancer treatment: Application to malignant mesothelioma","volume":"7","author":"Goricar","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102949","DOI":"10.1016\/j.critrevonc.2020.102949","article-title":"Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review","volume":"150","author":"Ahmadzada","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fonc.2019.01293","article-title":"Epigenetic regulation of miRNA expression in malignant mesothelioma: miRNAs as biomarkers of early diagnosis and therapy","volume":"9","author":"Tomasetti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"58606","DOI":"10.18632\/oncotarget.9686","article-title":"Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: Systematic review and qualitative meta-analysis","volume":"7","author":"Micolucci","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Weber, D.G., Johnen, G., Bryk, O., J\u00f6ckel, K.H., and Br\u00fcning, T. (2012). Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma\u2014A pilot study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030221"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Weber, D.G., Casjens, S., Johnen, G., Bryk, O., Raiko, I., Pesch, B., Kollmeier, J., Bauer, T.T., and Br\u00fcning, T. (2014). Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114483"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cncy.21646","article-title":"Young investigator challenge: MicroRNA-21\/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology","volume":"124","author":"Cappellesso","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9280170","DOI":"10.1155\/2017\/9280170","article-title":"Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma","volume":"2017","author":"Weber","year":"2017","journal-title":"Dis. Markers"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmoldx.2014.03.002","article-title":"Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma","volume":"16","author":"Andersen","year":"2014","journal-title":"J. Mol. Diagn."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","article-title":"Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism","volume":"7","author":"Melaiu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9645940","DOI":"10.1155\/2017\/9645940","article-title":"MicroRNA expression in malignant pleural mesothelioma and asbestosis: A pilot study","volume":"2017","author":"Mozzoni","year":"2017","journal-title":"Dis. Markers"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/1055-9965.EPI-18-0453","article-title":"Four-miRNA signature to identify asbestos-related lung malignancies","volume":"28","author":"Santarelli","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Santarelli, L., Strafella, E., Staffolani, S., Amati, M., Emanuelli, M., Sartini, D., Pozzi, V., Carbonari, D., Bracci, M., and Pignotti, E. (2011). Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018232"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2012.02.009","article-title":"Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients","volume":"45","author":"Tomasetti","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kresoja-Rakic, J., Szpechcinski, A., Kirschner, M.B., Ronner, M., Minatel, B., Martinez, V.D., Lam, W.L., Weder, W., Stahel, R., and Fr\u00fch, M. (2019). miR-625-3p and lncRNA GAS5 in liquid biopsies for predicting the outcome of malignant pleural mesothelioma patients treated with neo-adjuvant chemotherapy and surgery. Non-coding RNA, 5.","DOI":"10.3390\/ncrna5020041"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-018-2773-4","article-title":"Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins","volume":"75","author":"Karimi","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/biosci\/biv084","article-title":"Extracellular vesicles: Composition, biological relevance, and methods of study","volume":"65","author":"Zaborowski","year":"2015","journal-title":"Bioscience"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1039\/C8LC01193A","article-title":"Rapid and efficient isolation and detection of extracellular vesicles from plasma for lung cancer diagnosis","volume":"19","author":"Chen","year":"2019","journal-title":"Lab Chip"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1286095","DOI":"10.1080\/20013078.2017.1286095","article-title":"Obstacles and opportunities in the functional analysis of extracellular vesicle RNA\u2014An ISEV position paper","volume":"6","author":"Mateescu","year":"2017","journal-title":"J. Extracell. Vesicles"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.7150\/thno.22952","article-title":"The role of PTRF\/Cavin1 as a biomarker in both glioma and serum exosomes","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Navarro, A., Molins, L., Marrades, R.M., Moises, J., Vi\u00f1olas, N., Morales, S., Canals, J., Castellano, J.J., Ram\u00edrez, J., and Monzo, M. (2019). Exosome analysis in tumor-draining pulmonary vein identifies NSCLC patients with higher risk of relapse after curative surgery. Cancers, 11.","DOI":"10.3390\/cancers11020249"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/gcc.21926","article-title":"Analysis of exosome release and its prognostic value in human colorectal cancer","volume":"51","author":"Silva","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.drup.2019.100647","article-title":"Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance","volume":"47","author":"Vasconcelos","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-0759-6_10","article-title":"Extracellular vesicles and their roles in cancer progression","volume":"2174","author":"Chang","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.3748\/wjg.v26.i20.2570","article-title":"Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus","volume":"26","author":"Chiam","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Grange, C., Brossa, A., and Bussolati, B. (2019). Extracellular vesicles and carried miRNAs in the progression of renal cell carcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081832"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21873\/cgp.20023","article-title":"A proteomic analysis of the malignant mesothelioma secretome using iTRAQ","volume":"14","author":"Creaney","year":"2017","journal-title":"Cancer Genom. Proteom."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1096\/fj.201701291RR","article-title":"Exosomes from asbestos-exposed cells modulate gene expression in mesothelial cells","volume":"32","author":"Munson","year":"2018","journal-title":"FASEB J."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cavalleri, T., Angelici, L., Favero, C., Dioni, L., Mensi, C., Bareggi, C., Palleschi, A., Rimessi, A., Consonni, D., and Bordini, L. (2017). Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176680"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11688","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2019.08.001","article-title":"Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication","volume":"463","author":"Monaco","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"21346","DOI":"10.1038\/s41598-020-78422-y","article-title":"Enrichment of plasma extracellular vesicles for reliable quantification of their size and concentration for biomarker discovery","volume":"10","author":"Holcar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymeth.2012.09.015","article-title":"Assessing sample and miRNA profile quality in serum and plasma or other biofluids","volume":"59","author":"Blondal","year":"2013","journal-title":"Methods"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Donati, S., Ciuffi, S., and Brandi, M.L. (2019). Human circulating miRNAs real-time qRT-PCR-based analysis: An Overview of endogenous reference genes used for data normalization. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184353"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.20517\/2394-5079.2016.28","article-title":"Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma","volume":"2","author":"Shen","year":"2016","journal-title":"Hepatoma Res."},{"key":"ref_65","first-page":"D148","article-title":"miRTarBase 2020: Updates to the experimentally validated microRNA-target interaction database","volume":"48","author":"Huang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"W214","DOI":"10.1093\/nar\/gkq537","article-title":"The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function","volume":"38","author":"Donaldson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2013.02.016","article-title":"High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer","volume":"7","author":"Rasmussen","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1038\/ncomms12436","article-title":"miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells","volume":"7","author":"Rasmussen","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_70","first-page":"719","article-title":"MicroRNA profiles to predict postoperative prognosis in patients with small cell carcinoma of the esophagus","volume":"35","author":"Okumura","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.biopha.2018.03.043","article-title":"MicroRNA-625-3p promotes the proliferation, migration and invasion of thyroid cancer cells by up-regulating astrocyte elevated gene 1","volume":"102","author":"Fang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_72","first-page":"6475","article-title":"miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma","volume":"11","author":"Zhao","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"27805","DOI":"10.18632\/oncotarget.4738","article-title":"MiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells","volume":"6","author":"Zheng","year":"2015","journal-title":"Oncotarget"},{"key":"ref_74","first-page":"9560","article-title":"The decreased expression of miR-625 predicts poor prognosis of esophageal squamous cell carcinoma","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Roth, C., St\u00fcckrath, I., Pantel, K., Izbicki, J.R., Tachezy, M., and Schwarzenbach, H. (2012). Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038248"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jso.23380","article-title":"Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer","volume":"108","author":"Lou","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5724686","DOI":"10.1155\/2018\/5724686","article-title":"Expression of miR-652-3p and effect on apoptosis and drug sensitivity in pediatric acute lymphoblastic leukemia","volume":"2018","author":"Jiang","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/onc.2014.35","article-title":"miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma","volume":"34","author":"Zhou","year":"2015","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.18632\/oncotarget.14710","article-title":"microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.febslet.2012.05.050","article-title":"Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK","volume":"586","author":"Wang","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_81","unstructured":"Zhao, F., Fang, T., Liu, H., and Wang, S. (2020). Long non-coding RNA MALAT1 promotes cell proliferation, migration and invasion in cervical cancer by targeting miR-625-5p and AKT2. Panminerva Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12935-019-1070-0","article-title":"LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p\/NFIX axis","volume":"19","author":"Chen","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bueno, R., de Rienzo, A., Dong, L., Gordon, G.J., Hercus, C.F., Richards, W.G., Jensen, R.V., Anwar, A., Maulik, G., and Chirieac, L.R. (2010). Second generation sequencing of the mesothelioma tumor genome. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010612"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/epi-2016-0128","article-title":"Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer","volume":"8","author":"Rasmussen","year":"2016","journal-title":"Epigenomics"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Nymark, P., Lindholm, P.M., Korpela, M.V., Lahti, L., Ruosaari, S., Kaski, S., Hollm\u00e9n, J., Anttila, S., Kinnula, V.L., and Knuutila, S. (2007). Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genom., 8.","DOI":"10.1186\/1471-2164-8-62"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1165\/rcmb.2013-0053OC","article-title":"Asbestos-induced alveolar epithelial cell apoptosis. The role of endoplasmic reticulum stress response","volume":"49","author":"Kamp","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2902985","DOI":"10.1155\/2019\/2902985","article-title":"Screening of pleural mesothelioma cell lines for kinase activity may identify new mechanisms of therapy resistance in patients receiving platin-based chemotherapy","volume":"2019","author":"Borchert","year":"2019","journal-title":"J. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/jcmm.13182","article-title":"Targeting YAP in malignant pleural mesothelioma","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"42053","DOI":"10.18632\/oncotarget.5974","article-title":"MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data","volume":"6","author":"Pasello","year":"2015","journal-title":"Oncotarget"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/pin.12216","article-title":"Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations","volume":"64","author":"Chang","year":"2014","journal-title":"Pathol. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1089\/ars.2013.5215","article-title":"MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function","volume":"21","author":"Tomasetti","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"36338","DOI":"10.18632\/oncotarget.8916","article-title":"MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma","volume":"7","author":"Tomasetti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Weber, D.G., Brik, A., Casjens, S., Burek, K., Lehnert, M., Pesch, B., Taeger, D., Br\u00fcning, T., and Johnen, G. (2019). Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study. BMC Res. Notes, 12.","DOI":"10.1186\/s13104-019-4113-7"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Endzeli\u0146\u0161, E., Berger, A., Melne, V., Bajo-Santos, C., Sobo\u013cevska, K., \u0100bols, A., Rodriguez, M., \u0160antare, D., Rud\u0146ickiha, A., and Lietuvietis, V. (2017). Detection of circulating miRNAs: Comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3737-z"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Dai, Y., Cao, Y., Kohler, J., Lu, A., Xu, S., and Wang, H. (2021). Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes. BMC Genom., 22.","DOI":"10.1186\/s12864-020-07318-y"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1347019","DOI":"10.1080\/20013078.2017.1347019","article-title":"A comprehensive method for identification of suitable reference genes in extracellular vesicles","volume":"6","author":"Gouin","year":"2017","journal-title":"J. Extracell. Vesicles"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"15277","DOI":"10.1038\/s41598-017-15475-6","article-title":"Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression","volume":"7","author":"Grimolizzi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11912-018-0720-z","article-title":"The present and future of liquid biopsies in non-small cell lung cancer: Combining four biosources for diagnosis, prognosis, prediction, and disease monitoring","volume":"20","author":"Bracht","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-018-0683-0","article-title":"Development and Application of liquid biopsies in metastatic prostate cancer","volume":"20","author":"Morrison","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1586\/14737159.2015.1043272","article-title":"Cell-derived extracellular vesicles as a platform to identify low-invasive disease biomarkers","volume":"15","author":"Gonzalez","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"20360","DOI":"10.3402\/jev.v2i0.20360","article-title":"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research","volume":"2","author":"Witwer","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future","volume":"10","author":"Reid","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/10\/1014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:11:04Z","timestamp":1760166664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/10\/1014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":106,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jpm11101014"],"URL":"https:\/\/doi.org\/10.3390\/jpm11101014","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2021,10,9]]}}}